{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Moderna, Inc."},"Symbol":{"label":"Symbol","value":"MRNA"},"Address":{"label":"Address","value":"200 TECHNOLOGY SQUARE, CAMBRIDGE, Massachusetts, 02139, United States"},"Phone":{"label":"Phone","value":"+1 617 714-6500"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases."},"CompanyUrl":{"label":"Company Url","value":"https://www.modernatx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Brad Miller","title":"Chief Information Officer"},{"name":"Jerh Collins","title":"Chief Technical Operations & Quality Officer"},{"name":"St√©phane Bancel","title":"Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}